Immunotherapy shows promise for untreated rectal cancer in chinese patients

NCT ID NCT06640049

Ongoing Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a drug called dostarlimab in 23 Chinese patients with a specific type of advanced rectal cancer (dMMR/MSI-H) that has not been treated before. The goal is to see if the drug can make the cancer disappear completely and stay gone for at least 12 months. Patients receive the drug alone, without chemotherapy or radiation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED RECTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rectal neoplasm rectum adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEOPLASMS, RECTAL

Contacts and locations

Locations

GSK Investigational Site

Chengdu, 610041, China
GSK Investigational Site

Chongqing, 400010, China
GSK Investigational Site

Guangzhou, 510060, China
GSK Investigational Site

Guangzhou, 510655, China
GSK Investigational Site

Hangzhou, 310016, China
GSK Investigational Site

Hangzhou, China
GSK Investigational Site

Jinan, 250117, China
GSK Investigational Site

Kunming, 650106, China
GSK Investigational Site

Shanghai, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.